Edaravone clinical trials
Also written MCI-186, Radicut, MT-1186 and Radicava.
How each study uses Edaravone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Edaravone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 May 2017 · RADICAVA · NDA 209176 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2021 (7)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2004 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 17
Shionogi (18) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · Beijing Suncadia Pharmaceuticals Co., Ltd (1) · Shanghai Auzone Biological Technology Co., Ltd. (1) · Hui-Sheng Chen (1) · Nanjing Yoko Biomedical Co., Ltd. (1) · Kumamoto University (1) · Combination Therapy for Acute Ischemic Stroke Study Group (1)
Often tested with
Tested in the same studies.
Dexborneol (8) · HRS-8829 (1) · Taurine (1) · Nerve Growth Factor (1) · Scopolamine (1) · Atropine (1) · Dexmedetomidine (1) · Urinastatin (1)
Related medicines
As reviewed, each with the page that says it.
- One of Neuroprotective Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Edaravone.
- Dec 2026Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokePhase 4 · Shandong Provincial Hospital
Studies
Open first, then newest update. How each study uses Edaravone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 38
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokeRecruitingPhase 4Shandong Provincial HospitalNCT07933692Written as Edaravone
- Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment StudyRecruitingPhase 4Chuansheng ZhaoNCT07454473Written as Edaravone Dexborneol
- Edaravone in the Treatment of Optic NeuritisRecruitingNot applicableFirst Affiliated Hospital of Guangxi Medical UniversityNCT05540262Written as Edaravone
- Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic StrokeNot yet recruitingPhase 4Yi YangNCT06645522Written as Edaravone dexborneol
- Treatment of Acute Ischemic Stroke With Rt-PA Combined With Edaravone DexborneolRecruitingPhase 4The Second Hospital of Hebei Medical UniversityNCT06248242Written as Edaravone dexborneol
- Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic StrokeCompletedPhase 4ShionogiNCT00200356Written as Edaravone
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral SclerosisCompletedPhase 3ShionogiNCT01492686Written as MCI-186
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 3ShionogiNCT00330681Written as MCI-186
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification IIICompletedPhase 3ShionogiNCT00415519Written as MCI-186
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 3ShionogiNCT00424463Written as MCI-186
- Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALSCompletedPhase 3ShionogiNCT05568615Written as MT-1186
- Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With GastrostomyCompletedPhase 1ShionogiNCT04254913Written as MT-1186
- Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic StrokeCompletedPhase 2ShionogiNCT00821821Written as MCI-186
- Study of Oral Edaravone in Healthy Adult MalesCompletedPhase 1ShionogiNCT04481750Written as MT-1186
- PK Study in Subjects With Severe Hepatic ImpairmentCompletedPhase 1ShionogiNCT03664544Written as MCI-186
- Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)CompletedPhase 1ShionogiNCT04481789Written as MT-1186
- Comparative Bioavailability Study of Oral Edaravone Administered Orally and Via a Nasogastric TubeCompletedPhase 1ShionogiNCT04776135Written as MT-1186
- Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral SclerosisCompletedPhase 1ShionogiNCT04176224Written as MT-1186
- Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult SubjectsCompletedPhase 1ShionogiNCT04493281Written as MT-1186
- Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic ImpairmentCompletedPhase 1ShionogiNCT03289234Written as MCI-186
See all 38 studies that test Edaravone →
Given beside what is tested · 2 — Edaravone is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with Edaravone
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic StrokeSuspendedPhase 2Nanjing Yoko Biomedical Co., Ltd.NCT04984577Written as Edaravone Injection
- Study of Compound Edaravone Injection for Treatment of Acute Ischemic StrokeCompletedPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT02430350Written as Edaravone Injection
- Compound Edaravone Injection for Acute Ischemic StrokeCompletedPhase 2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT01929096Written as Edaravone Injection
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokeNov 12, 2026NCT07933692
Codes
What other systems call Edaravone · ClinicalTrials.gg INT006749
- MeSH (NLM) D000077553EdaravoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) S798V6YJRPEDARAVONEConfirmed FDA, NLM, Wikidata
- RxNorm 1921877Confirmed FDA, Wikidata
- Wikidata Q335099edaravoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74323EdaravoneConfirmed FDA, Wikidata
- DrugBank DB12243One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077553 | Edaravone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | S798V6YJRP | EDARAVONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1921877 | — | Confirmed FDA, Wikidata |
| Wikidata | Q335099 | edaravone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74323 | Edaravone | Confirmed FDA, Wikidata |
| DrugBank | DB12243 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.